Prenatal Antiseizure Medications Linked to Poor Fetal Growth Risks
[SUBJECT]
Personalized briefing
Discovery of the day · Neurology
Antiseizure medication use in pregnancy and the risk of poor fetal growth in the EURAP international registry: a prospective cohort study
Dear Damien Boorman, this is your personalized scientific intelligence briefing — curated for your work in Neurology.
Key finding
Medicine · Neurology
Discovery of the day
A large prospective cohort study from the EURAP international registry demonstrates that prenatal exposure to antiseizure medications is associated with an increased risk of poor fetal growth, independent of the well-established risks of congenital malformations and neurodevelopmental effects. The researchers found that the risk varies across individual antiseizure monotherapies and specific drug combinations, and escalates with the number of concomitant antiseizure medications used during pregnancy. For your work in preclinical models of chronic pain and your interest in personalized treatment strategies, this evidence underscores the need for individualized risk prediction in preconception counselling for women with epilepsy, a consideration that may extend to other neurological populations requiring antiseizure therapy.
Novelty
88%
Rigor
94%
Significance
92%
Validity
91%
Clarity
89%
Advertisement
GroupRFQ — join group deals on lab & medical equipment. Pool orders, unlock volume pricing. See open deals →
Your briefing is personalized based on your selected fields, keywords, and research interests.
